Cancer Immunity (10 February 2006) Vol. 6, p. 3
نویسندگان
چکیده
In order to establish a rationale for immunotherapy for lung cancer, we have investigated immunological characteristics of tumorassociated antigens (TAAs) discovered through molecular approaches. Preexisting Abs specific to these predicted TAAs were examined using specimens of lung pleural effusions (LPEs) and sera in non-small cell lung cancer (NSCLC) patients. The novel cancertestis (CT) antigens L514S and L552S were highly expressed in approximately half of the NSCLC tissues and established cell lines examined. When lung cancer patients in the USA and Japan were screened, 13%, 17%, and 5% were found to have Abs specific to recombinant L514S, L552S, and NY-ESO-1 proteins, respectively, whereas 48 normal donors had no Abs to these three CT antigens. The Ab titers specific to recombinant L552S and L514S proteins were similar to, and slightly lower than, Abs specific to NY-ESO-1 in stage IV NSCLC patients. To further characterize the preexisting specific Abs, the epitopes were analyzed using 20-aa length peptides entirely covering both antigens. An epitope common to the patients’ L514Sspecific Abs was identified as aa 85-100 and multiple epitopes, including a major epitope (aa 141-160), were identified for L552Sspecific Abs. The Ab epitopes thus identified are not found in human, animal, or bacterial proteins, other than L514S, L552S, or XAGE-1. These data clearly demonstrate that both molecularly defined CT antigens L514S and L552S are immunogenic, at least in terms of humoral responses, suggesting that both CT antigens are promising candidates for immunotherapy.
منابع مشابه
Cancer Immunity (22 March 2006) Vol. 6, p. 6
1Multidisciplinary Oncology Centre (CePO), Lausanne, Switzerland 2Ludwig Institute for Cancer Research (LICR), Lausanne Branch, Lausanne, Switzerland 3Department of Visceral Surgery, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland 4National Centre for Competence in Research (NCCR) Molecular Oncology, Swiss Institute for Experimental Cancer Research (ISREC), Epalinges, Swi...
متن کاملCancer Immunity (6 February 2008) Vol. 8, p. 3
1Ludwig Institute for Cancer Research, New York Branch at Memorial Sloan-Kettering Cancer Center, New York, NY, USA 2The Laboratory of Cell Growth Regulation, Department of Cell Signaling, Institute of Molecular Biology and Genetics, Kyiv, Ukraine 3Department of Biochemistry and Molecular Biology, University College London, London, United Kingdom 4Ludwig Institute for Cancer Research, BioMedica...
متن کاملCancer Immunity (21 April 2006) Vol. 6, p. 8
1Flaherty Comparative Oncology Laboratory, Donaldson-Atwood Cancer Clinic, The Animal Medical Center, 510 East 62nd Street, New York, NY 10021, USA 2Swim Across America Laboratory, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA 3Genitourinary Oncology Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021,...
متن کاملCancer Immunity (19 February 2009) Vol. 9, p. 1
1Medical Oncology, National Center for Tumor Diseases, University of Heidelberg, Heidelberg, Germany 2Department of Applied Tumor Biology, Institute of Pathology, University of Heidelberg, Heidelberg, Germany 3Hamamatsu Tissue Imaging and Analysis (TIGA) Center, BIOQUANT, University of Heidelberg, Heidelberg, Germany 4Institute of Pathology, University of Heidelberg, Heidelberg, Germany 5Depart...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره شماره
صفحات -
تاریخ انتشار 2005